Therefore, it will be important to dissect the pro- and antitumorigenic activities of the senescence secretome to pave the way toward a novel type of TRAIL-based apoptogenic therapy that targets premalignant/benign cancers. This evidence concerns the gene TNFSF10 and cancer.